Highlighted as game changer in drug development & delivery special feature on innovative technologies for improving drug solubility and bioavailability
Aveir VR is specifically designed to be retrieved when therapy needs to evolve or the device needs to be replaced
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
During her tenure at the University of South Florida Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend’s two product candidates, AL001 and AL002
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
It is currently available in tablet and injectable dosage forms
It also secures US $ 10 million for US launch and commercialization
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
The investment will significantly enhance the development of high-purity lipid systems, essential delivery systems for next generation nucleic acid drugs such as mRNA vaccines
Subscribe To Our Newsletter & Stay Updated
